VeinRx Inc., a Miami, Fla.-based developer of a way to deliver fluids to the peripheral vasculature, has raised $15 million in Series B funding. De Novo Ventures led the deal, and was joined by return backers Three ArchPartners and CHL Medical Partners.

VeinRx Inc is a privately held medical device company founded in July 2001 to develop minimally invasive devices to treat venous reflux disease (varicose veins) and was initially a wholly owned subsidiary of Syntheon LLC.

Varicose veins are caused by incompetent venous valves in the lower extremities resulting in swelling, pain, skin changes, and unsightly cosmetic features. VeinRx's first product is a proprietary infusion catheter system. The catheter is used to temporarily occlude targeted vessels and then deliver a uniform dose of a physician specified agent to the vessel segment.

www.vein-rxinc.com